Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • TER-2013-C01

    A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    Cancer Type: Solid tumor

    Biomarkers: AKT, PI3K, PTEN

    Phase: 1

    View Details on ClinicalTrials.gov

  • TCMCB07-01

    Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Phase: 2

    View Details on ClinicalTrials.gov

  • M24-533

    Phase 2, randomized master protocol study to evaluate safety and efficacy of multiple treatment combinations with telisotuzumab adizutecan in subjects with mets colorectal cancer.

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Phase: 2

    View Details on ClinicalTrials.gov

  • R1979-HM-2293

    A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

    Cancer Type: Lymphoma

    Lines of Therapy: 1

    Phase: 3

  • INBRX-106

    An Open-Label, multicenter, First in Human, Dose Escalation, Phase 1/2 Study of INBRX-106 in Subjects with locally advanced or metastatic solid tumors

    Cancer Type: NSCLC

    Lines of Therapy: 3, 2, 1

    Biomarkers: PD-L1

    Phase: 1

    View Details on ClinicalTrials.gov

  • Bria IMT, SV-BR-1-GM

    A Phase 3, randomized open label study comparing the Bria-IMT regimen in combination with CPI vs MD choice in metastatic breast cancer

    Cancer Type: BREAST

    Phase: 3

    View Details on ClinicalTrials.gov

  • BGB-16673-302

    A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

    Cancer Type: Leukemia, CLL

    Lines of Therapy: 2

    Phase: 3

    View Details on ClinicalTrials.gov

  • BGB-43995-302

    An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

    Cancer Type: BREAST

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • AMG-757-20250046

    A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
    View Details on ClinicalTrials.gov

  • 64007957MMY3005 Majestec-7

    Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy – MajesTEC-7

    Cancer Type: Multiple Myeloma

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content